A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response, published in Medecine Sciences and co-authoring Armand Bensussan, Jean-François Eliaou, Jérémy Bastid and Nathalie Bonnefoy (OREGA Biotech); Laurent Gros (INSERM); Carine Paturel and Ivan Perrot (Innate Pharma).

The review article (in French) is accessible online.

9 March 2020

Anti-CD39 immunotherapy reviewed in Medecine Sciences
9 March 2020

A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response, published in Medecine Sciences and co-authoring Armand Bensussan, Jean-François Eliaou, Jérémy Bastid and Nathalie Bonnefoy (OREGA Biotech); Laurent Gros (INSERM); Carine Paturel and Ivan Perrot (Innate Pharma). The review article (in French) is accessible online.
[ Read more ]
24 December 2019

JP Morgan conference, Jan. 13-16 2020, San Francisco
24 December 2019

Gilles Alberici, CEO and Jeremy Bastid, COO, will participate to the J.P. Morgan 38th Annual Healthcare Conference to be held 13-16 January 2020 in San Francisco, California, USA. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
[ Read more ]
19 December 2019

Season’s greetings
19 December 2019

From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !
[ Read more ]
7 November 2019

PRESS RELEASE – Novel ICI combination with aPD1 or aCTLA4
7 November 2019

– PRESS RELEASE – For immediate release   Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies   Lyon, France, November 7th, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, will showcase preclinical efficacy data of a novel regulator of response to anti-PD1 and anti-CTLA4 immunotherapies. “We are thrilled to share the data on this program”, commented Jeremy Bastid, Chief Operating Officer. “The target was identified as a master regulator of anti-PD1 and anti-CTLA4 response in resistant mouse models using our in vivo genetic screening platform”. Dr Bonnefoy further commented on the preclinical antibody data : “Similarly to the KO mice, the candidate mAb was shown to turn non-responders or partial responders to PD1 or CTLA4 targeting therapies into complete responders with long term survival in several mouse models. We have compelling evidence suggesting that the mechanism of action involves the reduction of myeloid cell infiltration as well as profound alterations in the tumor draining lymph nodes.” The data will be presented on November 9th, 2019 during the 34th SITC annual meeting held at the Gaylord National Hotel & Convention Center in National Harbor, MD, USA. The full abstract #P286 “In vivo genetic screens in PD-1 resistant mouse models identified modulator of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma” has now been released and is accessible online. The poster will be displayed on Saturday, November 9th, 7:00 am – 8:30 pm. Our team, Jeremy Bastid, Chief Operating Officer of OREGA Biotech and Nathalie Bonnefoy, acting Chief Scientific Officer, will be present during the poster sessions 12:35 – 2:05 pm and 7:00 – 8:30 pm to discuss the data and provide more information on the program. Download the press release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 and anti-CTLA4 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or […]
[ Read more ]